[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409352":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":51,"centralContacts":56,"locations":61,"responsibleParty":137,"collaborators":36,"id":140,"slug":36,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":141,"sex":147,"minAge":148,"maxAge":36,"enrollmentInfo":149,"targetDuration":36,"studyType":152,"phases":153,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":64,"whyStopped":36,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"standard","ACTIVE_COMPARATOR","External beam radiotherapy to deliver 5500 centiGray (cGy) in 20 fractions to the prostate over 4 weeks",[13],"Radiation: Hypofractionated external beam radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"High dose rate brachytherapy","EXPERIMENTAL","A single fraction of 19 Gray (Gy) is delivered to the prostate under anesthesia as an out patient.",[19],"Radiation: High dose rate brachytherapy",{"label":21,"type":16,"description":22,"interventionNames":23},"Permanent seed implant brachytherapy","A single permanent implant of radioactive Iodine-125 seeds is performed under anesthesia as an out patient to deliver 125 Gy to the prostate",[24],"Radiation: Permanent seed implant",{"label":26,"type":16,"description":27,"interventionNames":28},"Stereotactic body radiotherapy","36.25 Gy is delivered to the prostate in 5 fractions given either weekly or every second day, using a SABR technique.",[29],"Radiation: Stereotactic body radiotherapy",[31,37,40,46],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"RADIATION","Hypofractionated external beam radiotherapy","5500 cGy\u002F20 fractions delivered 5 days per week over 4 weeks",[9],null,{"type":32,"name":15,"description":38,"armGroupLabels":39,"otherNames":36},"A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance",[15],{"type":32,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"Permanent seed implant","Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance",[21],[45],"Low dose rate brachytherapy",{"type":32,"name":26,"description":47,"armGroupLabels":48,"otherNames":49},"External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.",[26],[50],"SABR",[52],{"name":53,"affiliation":54,"role":55},"Juanita Crook, MD","BCCancer","PRINCIPAL_INVESTIGATOR",[57],{"name":53,"role":58,"phone":59,"phoneExt":36,"email":60},"CONTACT","250 712 3958","jcrook@bccancer.bc.ca",[62,89,102,117],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"British Columbia Cancer Agency Center for the Southern Interior","RECRUITING","Kelowna","British Columbia","V1Y5L3","Canada",{"type":70,"coordinates":71},"Point",[72,73],-119.48568,49.88307,{"lat":73,"lon":72},[76,77,80,82,84,86,87],{"name":53,"role":58,"phone":59,"phoneExt":36,"email":60},{"name":78,"role":79,"phone":36,"phoneExt":36,"email":36},"Deidre Batchelar, PhD","SUB_INVESTIGATOR",{"name":81,"role":79,"phone":36,"phoneExt":36,"email":36},"Cynthia Araujo, PhD",{"name":83,"role":79,"phone":36,"phoneExt":36,"email":36},"David Kim, MD",{"name":85,"role":79,"phone":36,"phoneExt":36,"email":36},"Ross Halperin, MD",{"name":53,"role":55,"phone":36,"phoneExt":36,"email":36},{"name":88,"role":79,"phone":36,"phoneExt":36,"email":36},"Hamid Raziee, MD",{"facility":90,"status":91,"city":92,"state":66,"zip":36,"country":68,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Fraser Valley Cancer Center","NOT_YET_RECRUITING","Surrey",{"type":70,"coordinates":94},[95,96],-122.82509,49.10635,{"lat":96,"lon":95},[99],{"name":100,"role":58,"phone":36,"phoneExt":36,"email":101},"Winkle Kwan, MD","wkwan@bccancer.bc.ca",{"facility":103,"status":64,"city":104,"state":66,"zip":36,"country":68,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Vancouver Cancer Center","Vancouver",{"type":70,"coordinates":106},[107,108],-123.11934,49.24966,{"lat":108,"lon":107},[111,115],{"name":112,"role":58,"phone":113,"phoneExt":36,"email":114},"Raman Srinivas, MD","604-877-6000","srinivas.raman@bccancer.bc.ca",{"name":116,"role":55,"phone":36,"phoneExt":36,"email":36},"Srinivas Raman, MD",{"facility":118,"status":64,"city":119,"state":66,"zip":36,"country":68,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Vancouver Island Cancer Center","Victoria",{"type":70,"coordinates":121},[122,123],-123.35155,48.4359,{"lat":123,"lon":122},[126,129,131,133,135],{"name":127,"role":58,"phone":36,"phoneExt":36,"email":128},"Saibishkumar Elantholi Parmeswaran, MD","skumar@bccancer.bc.ca",{"name":130,"role":79,"phone":36,"phoneExt":36,"email":36},"Jordan Wong, MD",{"name":132,"role":79,"phone":36,"phoneExt":36,"email":36},"Jonathan Livergant, MD",{"name":134,"role":79,"phone":36,"phoneExt":36,"email":36},"Howard Pai, MD",{"name":136,"role":79,"phone":36,"phoneExt":36,"email":36},"Abe Alexander, MD",{"type":55,"investigatorFullName":138,"investigatorTitle":139,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Juanita Crook","Professor of Radiation Oncology","100409352",false,"NCT04610372","5500\u002F20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)","Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment","PROMPT","Inclusion Criteria:\n\n* Signed study specific informed consent\n* European Cooperative Oncology Group performance status 0 to 2\n* Histologically confirmed adenocarcinoma of the prostate\n* Any Tumor stage, any T, any N, M1\n* No prior therapy for prostate cancer apart from androgen deprivation\n* Planned for long-term androgen deprivation therapy (greater than 9 months in duration)\n* Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study\n* For brachytherapy arms, patient must be technically suitable for brachytherapy according to investigator, in terms of bladder function and prostate size.\n\nExclusion Criteria:\n\n* High metastatic burden defined as 5 or more bone metastases or visceral metastases\n* Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation\n* For Brachytherapy Arms =: Any prior Transurethral resection of prostate","MALE","18 Years",{"count":150,"type":151},168,"ESTIMATED","INTERVENTIONAL",[154],"NA","We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.",[157],"Oligometastatic Prostate Cancer",[159,160,161,162,163],"prostate adenocarcinoma","oligometastases","radiotherapy","hypofractionation","brachytherapy","2026-04-30",{"date":166,"type":167},"2026-05-06","ACTUAL",{"date":169,"type":167},"2021-07-12",{"date":171,"type":151},"2033-06-30",{"name":5,"class":6},4]